Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor's Novel Cell Therapy

LOS ANGELES, USA - Neurology(R), an international peer-reviewed journal, published the results of the HOPE-Duchenne clinical trial that evaluated the safety and efficacy of a single intracoronary dose of Capricor Therape...

First Mesothelioma Patient Dosed in CA-170 Study

LEXINGTON, Mass. - Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that the first mesothelioma patient has been enrolled an...

Remote Participation Enables Patients with ALK-Positive Lung Cancer from Across the Country to Participate in New Study of Treatment Resistance

SAN CARLOS, Calif. - The Addario Lung Cancer Medical Institute (ALCMI), a patient-founded not-for-profit global research consortium, and researchers from the Dana-Farber Cancer Institute are launching a novel nationwide ...

Targeted Treatment Shrinks Deadly Pediatric Brain Tumors

LA JOLLA, CA - Chemotherapy and radiation are effective cancer treatments because they kill rapidly dividing cells, including tumor cells. But for children--whose tiny bodies are still growing--these treatments can cause...

Can India Lead The Way in Neglected Diseases Innovation?

Nirmal Kumar Ganguly and colleaguescall for a comprehensive policy for neglected diseases research in India to foster innovation in drugs, diagnostics, and vaccines, critical for evolving needs of elimination programmesI...

Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine in Promoting the Restoration of Forgotten Memories in Mice and Healthy Volunteers

ZUG, Switzerland - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, hi...

Soligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs

Princeton, NJ - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

Orkambi Approved in Europe for Younger CF Patients with F508del Mutations

The European Commission has approved the label extension of Orkambi (lumacaftor/ivacaftor) for the treatment of children ages 2-5 with cystic fibrosis (CF) due to F508del mutations, Vertex Pharmaceuticals, the therapy's ...

FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency

ROCKVILLE, Md. - Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced...

Albireo Granted Orphan Drug Designation by FDA For Lead Product Candidate A4250 for Treatment of Biliary Atresia

BOSTON, Ma. - Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced the U.S. Food and Drug Administration (FDA) has granted orphan d...